ArticleMolecules (Basel, Switzerland)2026
An Ultrasensitive Label-Free Aptasensor for Insulin Detection Assisted by Exonuclease III and 2-Aminopurine.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
We designed a label-free fluorescent aptasensor assisted by exonuclease III (Exo III) for sensitive insulin (Ins) detection. The method has high sensitivity, anti-interference properties and repeatability. Additionally, the label-free fluorescent aptasensor assisted by Exo III used to detect Ins has not been reported on yet. In this study, we connected a modified DNA sequence to the 5' end of an aptamer, modifying it into a hairpin structure and exposing 11 nucleotides at the 3' end containing the base adenine (A). The A was substituted with base 2-aminopurine (2AP) to provide a label-free stable hairpin fluorescent probe (2AP-hairpin probe). This strategy took advantage of the high binding affinity of the Ins aptamer and the susceptibility of 2AP to the local base stacking environment. When Ins is added to the detection system, the 2AP-hairpin probe binds to Ins, adopts a folded state, and blocks Exo III's access to the binding site for cutting DNA. 2AP cannot be released, and the fluorescence of the 2AP-hairpin probe/cDNA/Ins/Exo III system cannot be restored. Ins detection is achieved by comparing changes in the fluorescent intensity before and after adding Ins to the detection system. The detection limit of the aptasensor is as low as 1.62 nM with a linear range of 3-130 nM. Furthermore, it is able to selectively and directly detect Ins in biological fluids, demonstrating significant clinical application value and research significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.